股 票 研 究 业绩短期承压，新品打造新增长动能 仙琚制药(002332) 仙琚制药 2025 年半年报业绩点评 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | | --- | --- | --- | --- | | 吴晗(分析师) | 010-83939773 | wuhan3@gtht.com | S0880523080005 | | 余文心(分析师) | 021-38676666 | yuwenxin@gtht.com | S0880525040111 | 本报告导读： 存量业务短期承压，2025H2 有望改善，创新管线逐步推进。 投资要点： | [Table_Finance] 财务摘要(百万元) | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入 | 4,123 | 4,001 | 3,910 | 4,327 | 4,898 | | (+/-)% | -5.9% | -3.0% | -2.3% | 10.7% | 13.2% | | 净利润(归母) ...

Investment Rating - The report maintains an "Accumulate" rating for the industry [5] Core Insights - The pharmaceutical and biotechnology industry is expected to experience a turning point and growth resonance, with a focus on the resilience of the raw material drug sector amidst various macro and micro factors [7][10] - The industry is characterized by a significant number of listed companies, totaling 494, with a total market value of 77,409.20 billion and a circulating market value of 70,487.38 billion [2] Summary by Sections Industry Overview - The report analyzes 47 representative raw material drug companies, indicating that despite pressures on revenue, the profit margins are showing improvement, reflecting the industry's resilience [10] - The average revenue growth rate for the 47 companies in the first half of 2025 was -5.38%, while the average growth rate of non-recurring net profit was 14.43% [10][12] Financial Performance - Key companies such as Xinhecheng, Aoruite, Tianyu Co., Meinuohua, and others have achieved over 10% growth in revenue and non-recurring net profit [10] - The report highlights that the non-recurring net profit of Xinhecheng increased significantly by 70.50% year-on-year in the first half of 2025 [10] Market Trends - The report notes that the prices of major raw materials are currently at low levels, particularly for certain categories like sartans and heparins, with expectations for gradual price recovery as excess capacity is cleared [7][10] - The investment strategy for the second half of the year focuses on identifying companies that are at a turning point in their existing business while also exploring new growth opportunities [7][10] Company Recommendations - The report suggests focusing on companies such as Tianyu Co., Sitaly, Tonghe Pharmaceutical, Meinuohua, Xianju Pharmaceutical, and Puluo Pharmaceutical for potential investment opportunities [7][10]

南方中证1000ETF（512100）基金经理为崔蕾。 截至发稿，崔蕾累计任职时间6年295天，现任基金资产总规模949.76亿元，任职期间最佳基金回报 125.3%， 任职期间最差基金回报-24.18%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 8月27日，仙琚制药跌5.04%，截至发稿，报10.92元/股，成交5.88亿元，换手率5.34%，总市值108.02亿 元。 资料显示，浙江仙琚制药股份有限公司位于浙江省仙居县福应街道现代工业集聚区丰溪西路15号，成立 日期2000年6月26日，上市日期2010年1月12日，公司主营业务涉及甾体原料药和制剂的研制、生产与销 售。主营业务收入构成为：皮质激素63.39%，妇科及计生用药20.69%，其他9.21%，麻醉及肌松用药 6.71%。 从仙琚制药十大流通股东角度 数据显示，南方基金旗下1只基金位居仙琚制药十大流通股东。南方中证1000ETF（512100）二季度增 持140.94万股，持有股数 ...

金融工程 证 券 研 究 报 告 市场形态周报（20250901-20250905） 本周指数普遍下跌 本周市场回顾与最新信号 从本周的指数表现来看，本周指数普遍下跌，其中沪深 300 下跌 0.81%，中证 500 下跌 1.85%，中证 1000 下跌 2.59%。 当前，上证 50 的隐含波动率为 19.73%，相对于上周下跌了 3.32%。上证 500 的隐含波动率为 23.4%，相对于上周下跌了 2.33%。中证 1000 的隐含波动率 为 25.94%，相对于上周下跌了 0.55%。沪深 300 的隐含波动率为 20.27%，相 对于上周下跌了 3.29%。 我们统计了最近信号的次数和胜率。2025 年 8 月 25 日到 2025 年 8 月 29 日正 面信号共出现了 2442 次，未来高点平均胜率为 28.76%，负面信号出现 3750 次，未来低点平均胜率为 70.79%。 从宽基择时策略来看，上证 50、恒生等权重、恒生指数、恒生可持续发展企业 指数、恒生香港 35 出现看多信号，其余宽基信号为中性。 出现连续看多信号股票、特殊看多信号股票和券商金股出现看多信号股票见正 文。 更多具体详 ...

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Views - The company's performance is under short-term pressure, but improvement is expected in the second half of the year [1] - Revenue and profit forecasts have been adjusted, with earnings per share projected at 0.61, 0.70, and 0.86 yuan for 2025-2027, respectively [2] - The target price is set at 12.81 yuan based on a 17x P/E ratio for 2026 [2] Financial Performance Summary - The company reported a revenue of 4,123 million yuan in 2023, with a projected decline to 3,837 million yuan in 2025, followed by a recovery to 4,429 million yuan in 2026 and 5,181 million yuan in 2027 [4] - The gross margin is expected to improve from 52.9% in 2023 to 65.0% by 2027 [4] - The net profit attributable to the parent company is forecasted to increase from 563 million yuan in 2023 to 852 million yuan in 2027, with a significant jump of 51.9% in 2025 [4] - The company’s earnings per share are projected to rise from 0.57 yuan in 2023 to 0.86 yuan in 2027 [4] Market and Product Insights - The company is experiencing challenges in raw material and formulation sales, but there is potential for recovery as export prices stabilize and the impact of centralized procurement diminishes [8] - The overseas market is becoming a new growth driver, with a reported revenue of 5.41 billion yuan from international operations, reflecting a 5.1% year-on-year increase [8] - The company has a robust pipeline of new products, with several new drugs and complex formulations expected to receive approval soon, enhancing future growth prospects [8]

Investment Rating - The investment rating for Xianju Pharmaceutical (002332.SZ) is "Buy" (maintained) [1][3][18] Core Views - The report indicates that negative factors are gradually being resolved, and a transition between old and new growth drivers is expected, making an inflection point worth anticipating [1][3] - The company's performance is under pressure due to intensified competition in raw materials and pricing pressures in the formulation business, but there are signs of recovery with new product approvals and a potential turnaround in performance [3][4] Financial Performance Summary - For 2025H1, the company achieved revenue of 1.869 billion yuan, a year-on-year decrease of 12.56%, and a net profit attributable to shareholders of 308 million yuan, down 9.26% year-on-year [3][5] - The revenue for 2025 is projected to be 3.986 billion yuan, with a slight decline of 0.36%, followed by growth rates of 11.70% and 15.85% in 2026 and 2027, respectively [1][3] - The net profit attributable to shareholders is expected to be 632 million yuan in 2025, reflecting a significant year-on-year increase of 59.10% [1][3] Segment Performance - The formulation segment's revenue for 2025H1 was 1.127 billion yuan, down 7.2%, with respiratory products showing stable growth [3][4] - The raw materials and intermediates segment saw a revenue decline of 20% in 2025H1, but the Italian subsidiary has resumed growth [3][4] Cost and Profitability Metrics - The gross margin for 2025H1 was 63.16%, an increase of 8.32 percentage points, attributed to a higher proportion of high-margin formulation revenue [3][5] - The report notes an increase in the selling expense ratio to 29.30% and a management expense ratio of 8.80% for 2025H1 [3][5] Research and Development - The company continues to advance its R&D efforts, with several new products approved for production and ongoing clinical trials for innovative drugs [3][4]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2] Core Views - The company reported a revenue of 1.869 billion yuan in the first half of 2025, a decrease of 12.56% year-on-year, with a net profit attributable to shareholders of 308 million yuan, down 9.26% [7] - The decline in performance is attributed to falling raw material prices and the impact of centralized procurement on the revenue from generic drugs and existing products [7] - The company has a rich pipeline of new formulations, with four products approved for production and several others in the research phase, indicating potential growth in the future [7] - The forecast for revenue from 2025 to 2027 is 3.836 billion yuan, 4.368 billion yuan, and 5.058 billion yuan respectively, with net profits expected to be 572 million yuan, 660 million yuan, and 776 million yuan [7] Financial Summary - Revenue for 2023 is projected at 4.123 billion yuan, with a revenue growth rate of -5.9% [6] - The net profit for 2023 is estimated at 563 million yuan, with a net profit growth rate of -24.9% [6] - The company’s earnings per share (EPS) for 2025 is expected to be 0.58 yuan, with a price-to-earnings (PE) ratio of 18.6 [6] - Return on equity (ROE) is projected to be 9.2% in 2025, improving to 11.5% by 2027 [6] Market Performance - The company's stock has underperformed compared to the CSI 300 index, with a decline of 23% over the past 12 months [4]

Group 1: Financial Performance - The projected net profit for 2025 is estimated at 605 million RMB, reflecting a growth rate of 52% compared to 2024[1] - The expected operating revenue for 2025 is 4,157 million RMB, with a growth rate of 4% from 2024[1] - The estimated EPS for 2025 is 0.6, with a PE ratio of 18[1] Group 2: Market Trends and Risks - The valuation for 2025-2027 is projected at 18x, 16x, and 14x, with a PEG ratio of less than 1 for 2026[1] - The company is expected to launch innovative and hard-to-replicate products, including a new drug expected to be approved in 2025[1] - Risks include fluctuations in customer demand and potential delays in product development[1] Group 3: Industry Insights - The pharmaceutical industry is experiencing a gradual recovery, with the raw material drug business stabilizing[1] - The beverage industry is expected to see improved sales during the Mid-Autumn Festival and National Day, with a narrowing decline[1] - The semiconductor equipment sector is projected to achieve significant revenue growth, with a target of 5 billion RMB by 2025[1]

根据市场公开信息及8月28日披露的机构调研信息，知名私募呈瑞投资近期对5家上市公司进行了调研， 相关名单如下： 1）仙琚制药 （呈瑞投资参与公司电话会议） 仙琚制药2025年中报显示，公司主营收入18.69亿元，同比下降12.56%；归母净利润3.08亿元，同比下 降9.26%；扣非净利润2.67亿元，同比下降19.52%；其中2025年第二季度，公司单季度主营收入8.61亿 元，同比下降21.72%；单季度归母净利润1.64亿元，同比下降12.89%；单季度扣非净利润1.23亿元，同 比下降34.15%；负债率16.73%，投资收益-961.69万元，财务费用-488.5万元，毛利率63.16%。 调研纪要：珀莱雅2025年半年度分红方案现金分红总额占归母净利润的比例提升到接近40%，未来将保 持优秀、可持续的分红。公司筹划港股上市，旨在全球化发展，提供充足资金支持，提升品牌形象和知 名度，增强股东回报。董事会新增独立董事范明曦女士和职工代表董事，新聘任董事会秘书薛霞女士。 2025年上半年毛利率提升至73.38%，销售费用率增加因品牌投入加大。大单品策略取得显著成效，未 来将继续迭代和品类延展。彩棠品牌深 ...

Core Insights - Xianju Pharmaceutical announced its R&D expenses for the first half of 2025 to be 126 million yuan, with an R&D expense ratio of 6.7%, compared to 125 million yuan and 5.8% in the same period last year [2] Group 1: R&D Investment - The company aims to maintain a suitable level of investment and growth in R&D expenses that aligns with its development stage [2] - The company is transitioning from a traditional generic drug manufacturer to a high-barrier formulation producer, which involves risks and challenges [2] Group 2: Market Challenges - The company is actively responding to challenges posed by national and provincial alliance procurement through innovation in R&D [2]